FKBP12 PROTAC dTAG-13

未知

FKBP12 蛋白激酶 dTAG-13

FKBP12 PROTAC dTAG-13

F648183-5mg

5mg

≥99%

-20°C储存

超低温冰袋运输

FKBP12 PROTAC dTAG-13 (dTAG-13), a PROTAC-based heterobifunctional degrader, is a selective degrader of FKBP12 F36V with expression of FKBP12F36V in-frame with a protein of interest. FKBP12 PROTAC dTAG-13 effectively engages FKBP12 F36V and CRBN, thereby selectively degrading FKBP12 F36V In Vitro TAG-13 (1-1000 nM; 4 hours; 293FT WT cells) treatment potently reduces FKBP12 F36V -Nluc levels in 293FT WT cell, indicating the requirement of CRBN for the observed effects. Treatment of MV4;11 cells expressing BRD4(short)-FKBP12 F36V with dTAG-13 leads to robust degradation of BRD4. dTAG-13 treatment leads to rapid degradation of BRD4 within one hou. dTAG-13 treatment leads to rapid and potent degradation of the BRD4 fusion chimera in the heterozygous and homozygous knock-in clones, with no effect on endogenous FKBP12 WT. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: 293FT WT cells Concentration: 1 nM, 10 nM, 100 nM, 1000 nM Incubation Time: 4 hours Result: Potently reduced FKBP12 F36V -Nluc levels in 293FT WT cell. In Vivo Following bone marrow engraftment of MV4;11 cells expressing luc-FKBP12F36V in mice, the bioluminescent signal after vehicle or dTAG-13 administration is monitored. A significant, rapid, and durable effect on bioluminescent signal is observed four hours after dTAG-13 administration, indicating effective degradation of luc-FKBP12F36V. Twenty-eight hours following the final treatment, the recovery of cellular bioluminescence to levels comparable between vehicle and dTAG-13 treatment groups is observed . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:Cereblon FKBP12(F36V)

FKBP12 PROTAC dTAG-13 (dTAG-13)是一种基于 PROTAC 的异功能降解剂，它是一种 FKBP12 F36V 的选择性降解剂，可将 FKBP12F36V 与感兴趣的蛋白质同框表达。FKBP12 PROTAC dTAG-13 能有效地与 FKBP12 F36V 和 CRBN 结合，从而

2064175-41-1

C57H68N4O15

1049.17 g/mol

124187630

CC[C@@H](C1=CC(=C(C(=C1)OC)OC)OC)C(=O)N2CCCC[C@H]2C(=O)O[C@H](CCC3=CC(=C(C=C3)OC)OC)C4=CC=CC=C4OCC(=O)NCCCCCCOC5=CC=CC6=C5C(=O)N(C6=O)C7CCC(=O)NC7=O

[(1R)-3-(3,4-dimethoxyphenyl)-1-[2-[2-[6-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxyhexylamino]-2-oxoethoxy]phenyl]propyl] (2S)-1-[(2S)-2-(3,4,5-trimethoxyphenyl)butanoyl]piperidine-2-carboxylate

1S/C57H68N4O15/c1-7-37(36-32-47(71-4)52(73-6)48(33-36)72-5)54(65)60-29-14-12-19-41(60)57(68)76-43(25-22-35-23-26-44(69-2)46(31-35)70-3)38-17-10-11-20-42(38)75-34-50(63)58-28-13-8-9-15-30-74-45-21-16-18-39-51(45)56(67)61(55(39)66)40-24-27-49(62)59-53(40)64/h10-11,16-18,20-21,23,26,31-33,37,40-41,43H,7-9,12-15,19,22,24-25,27-30,34H2,1-6H3,(H,58,63)(H,59,62,64)/t37-,40?,41-,43+/m0/s1

BJFBRLAWLPZOMJ-QHVFGHLPSA-N

CCC(C1=CC(=C(C(=C1)OC)OC)OC)C(=O)N2CCCCC2C(=O)OC(CCC3=CC(=C(C=C3)OC)OC)C4=CC=CC=C4OCC(=O)NCCCCCCOC5=CC=CC6=C5C(=O)N(C6=O)C7CCC(=O)NC7=O

124187630

DMSO : 180 mg/mL (171.56 mM; Need ultrasonic)

2

15

27

1048.47 Da

1048.47 Da

224.000 Ų

76

0

1930

0

1

7.4